Pei Yin*1, Jinpeng Jia†1, Jijun Li*, Yan Song*, Yiyan Zhang*, Fengkun Chen*
Oncology Research, Vol.24, No.1, pp. 65-72, 2016, DOI:10.3727/096504016X14587366983838
Abstract Renal cell carcinoma (RCC) is the most common malignancy in the kidney in the world, and the 5-year overall survival for patients remains poor due to the lack of effective treatment strategies. Although ABT-737, as
a Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic reagent, apoptosis induced by
ABT-737 is often blocked in several types of cancer cells. This study investigated whether the combination of
the small-molecule BH3 mimetic ABT-737 and the lysosome inhibitor chloroquine was an effective strategy
for treating renal cancer cells. We found that the combination of ABT-737 and chloroquine… More >
Login
Register
